Could RO7851624, newly into clinical trials, be RG6735?
ApexOnco Front Page
Recent articles
The company sidelines CDK2 and pan-KRAS blockers, among other projects.
Ideaya discontinues IDE275 and IDE705, previously ditched by GSK.
No sooner does one gammadelta-focused biotech die than another takes its place.
The Viktoria-1 trial of gedatolisib is a hit in PIK3CA-mutant, as well as in wild-type disease.
Full US approval of Gilead’s Tecartus was the only positive decision last month.
The two companies have been involved in recent licensing deals.
ASCO looms, while FDA decisions are due on Enhertu and Inqovi.
